Mannkind (MNKD) Amortizatization of Intangibles (2019 - 2026)
Mannkind (MNKD) reported Amortizatization of Intangibles of $532000.0 for Q1 2026, down 2.21% year-over-year from $544000.0 in Q1 2025, and up 188.23% quarter-over-quarter from -$603000.0 in Q4 2025.
Mannkind (MNKD) Amortizatization of Intangibles (2019 - 2026) Analysis & Trends
Mannkind (MNKD) has 8 years of Amortizatization of Intangibles data on file, last reported at $532000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $532000.0, down 2.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 36.31% YoY), and the FY2025 annual result was $1.2 million, down 27.34% from the prior year.
- Amortizatization of Intangibles advanced to $532000.0 in Q1 2026 per MNKD's latest filing, from -$603000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.0 million in Q2 2022 and troughed at -$603000.0 in Q4 2025.
- A 5-year average of $452941.2 and a median of $332000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2025: Amortizatization of Intangibles surged 468.8% in 2022, then sank 214.2% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $332000.0 in 2022, then slipped by 2.71% to $323000.0 in 2023, then surged by 63.47% to $528000.0 in 2024, then slumped by 214.2% to -$603000.0 in 2025, then jumped by 188.23% to $532000.0 in 2026.
- Business Quant data shows MNKD's Amortizatization of Intangibles at $532000.0 in Q1 2026, -$603000.0 in Q4 2025, and $740000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | 532,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | -603,000.00 |
| Dec 31, 2025 | -603,000.00 |
| Sep 30, 2025 | 740,000.00 |
| Sep 30, 2025 | 740,000.00 |
| Jun 30, 2025 | 531,000.00 |
| Jun 30, 2025 | 531,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Mar 31, 2025 | 544,000.00 |
| Dec 31, 2024 | 528,000.00 |
| Dec 31, 2024 | 528,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Sep 30, 2024 | 493,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Jun 30, 2024 | 319,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Mar 31, 2024 | 328,000.00 |
| Dec 31, 2023 | 323,000.00 |
| Dec 31, 2023 | 323,000.00 |